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Introduction 
Blood transfusion has been part of 
medical practice for hundreds of years, first 
pioneered in 1628.
1
 Blood has been used in 
various clinical settings with the intended 
benefit of increasing oxygen delivery 
capacity and increasing intra-vascular blood 
volume. During World War II, blood 
donation became a national priority as 
American soldiers were transfused with 
blood products in resuscitation efforts in the 
field after trauma. However, a few decades 
later, with the new knowledge of 
transmission of infectious diseases, there 
was greater caution with blood transfusion. 
In the 1970’s and 1980’s, the emergence of 
human immunodeficiency viruses (HIV) and 
viral hepatitis led to greater public 
awareness about the risks of receiving a 
blood transfusion. Even more recently, 
blood transfusion has come to be viewed as 
an organ transplant equivalent and multiple 
clinical studies have indicated that greater 
caution and care with transfusion should be 
taken. While blood transfusion remains a 
key intervention in medical practice, its risks 
and benefits must be weighed carefully by 
the provider and patient.   
The following are six clinical vignettes 
that highlight key concepts that are 
important in medical decision making 
regarding blood transfusions. 
 
Blood is Safer, But Still Has Risks 
Tom Jones (all patient names used in 
this report are fictitious) is a 55-year-old 
man admitted for melena and fatigue. 
His vital signs are stable and he reports 
no cardiac or pulmonary symptoms. On 
endoscopy, he has a gastric ulcer, which 
is treated appropriately and his melena 
ceases. On admission, the patient is 
found to have a hemoglobin of 8.0 g/dL 
and he is transfused with 1 unit of 
packed red blood cells. After discharge, 
his internist is notified by the blood bank 
that Mr. Jones was transfused with blood 
contaminated with hepatitis C that had 
not been detected on routine screening. 
The recipient was previously hepatitis 
negative. Whose responsibility is it to 
contact the patient and notify him of the 
contaminated transfusion? Was trans-
fusion even indicated? 
 
The incidence of hepatitis B, hepatitis C, 
and HIV have decreased in the pool of 
donated blood with improved screening and 
testing.
2
 The current risk of transmission of 
hepatitis B infections through blood 
transfusion is 1 in 200,000 to 500,000; 
hepatitis C is 1 in 1,390,000; and HIV is 1 in 
2,000,000.
3
 Patients must be counseled 
about the infectious risks of blood prior to 
transfusion. If contaminated blood is 
transfused, then it is the responsibility of the 
ordering provider and the blood bank to 
notify the patient of this complication.  
Potential non-infectious risks exist as 
well for the recipient of blood donation. 
Immunomodulation (transient adverse 
changes in the immune response) is a 
potential complication from blood 
transfusion.
4
 The hypothesized mechanism 
is that transfusion of allogeneic blood may 
upregulate humoral immunity, down-
regulate cellular immunity, and induce a 
proinflammatory state. This is an area of 
medicine under investigation, but it is 
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important to recognize its potential clinical 
effect. The increased incidence of post-
operative infection after blood transfusion 
and possible effect on increased tumor 
progression in cancer patients may be due to 
the immunomodulatory effects of allogeneic 
blood transfusion.
5
  
Comment. The transfusion of red blood 
cells was likely not indicated for Mr. Jones 
as he had no significant symptoms. Fatigue 
is not considered a serious symptom that 
requires transfusion for treatment. 
Evaluation of anemia likely would have 
shown iron deficiency and appropriate 
treatment with oral or parenteral iron would 
have improved the patient’s symptoms 
without blood transfusion. In this case of 
possible contamination of viral hepatitis in 
the transfused blood, it would be the 
responsibility of the attending physician and 
the blood bank to notify the patient. It is not 
within the scope of this article to review 
appropriate transfusion thresholds for 
various clinical conditions. Although the 
topic is highly nuanced, there are multiple 
studies that indicate most patients can reach 
a hemoglobin of 7 to 8 g/dL without adverse 
effects.
6-8
 
 
Inappropriate Transfusion May Lead to 
Adverse Outcomes 
Maria Garcia is a 39-year-old woman 
admitted to the ICU with severe sepsis 
secondary to bacterial pneumonia. She is 
treated with appropriate antibiotics and 
supportive care. On admission, her 
hemoglobin is 11.0 g/dL, but after 
multiple lab draws, blood loss with 
central venous catheter placement, and 
arterial catheter placement, her 
hemoglobin drifts down to 7.5 g/dL by 
day 5 of hospitalization. At this time, she 
is improving from the pneumonia, sepsis 
is resolved, and she likely will be 
transferred to the floor soon. The 
physician caring for her is considering a 
blood transfusion. What potential 
adverse outcomes should the physician 
anticipate? 
 
Blood transfusion can have potential 
negative clinical outcomes in a variety of 
clinical settings. These include increased 
mortality, risk for infection, and transfusion-
related complications. Hébert et al.
6
 
published the seminal study, Transfusion 
Requirements in Critical Care trial (TRICC) 
in 1999, which called into question long-
standing transfusion practices. In critically 
ill patients, there was no statistically 
significant difference in mortality between 
patients in the “liberal group” transfused at a 
trigger hemoglobin of less than 10 g/dL 
versus patients in the “restrictive group” 
transfused at a trigger of less than 7 g/dL. 
The liberally transfused group had 
significantly higher in-hospital mortality 
(28.1% versus 22.2%). This landmark study 
reframed the standard transfusion trigger to 
7 g/dL for most critically ill patients, which 
may be lower than what many physicians 
used in practice. 
In a large outcomes study of 1,915 
patients, Engoren et al.
7
 showed that in 
patients who underwent first time isolated 
coronary artery bypass surgery, mortality 
was higher for those who received blood 
transfusion. After adjustment for co-
morbidities, transfusion was associated with 
a 70% increase in mortality (risk ratio = 1.7, 
CI = 1.4-2.0, p = 0.001). A prospective 
study of 15,534 patients admitted to a Level 
I trauma center showed that blood 
transfusion was a strong independent 
predictor of mortality (p < 0.001), ICU 
admission (p < 0.001), ICU length of stay 
(LOS; p < 0.001) and hospital LOS (p < 
0.001) after controlling for severity of shock 
based on lactate, base deficit, shock index, 
and admission anemia.
9
 
In a meta-analysis of 20 peer-reviewed 
articles, allogeneic blood transfusion had an 
Kansas Journal of Medicine 2014                                                                                    Rethinking Blood Transfusion 
30 
 
increased risk of post-operative bacterial 
infection.
10
 The common odds ratio for the 
incidence of post-operative bacterial 
infection after transfusion was 3.45 (range 
1.43-15.15) with 17 of 20 articles 
demonstrating p values less than or equal to 
0.05. The odds ratio was greater in a sub-
analysis of trauma patients at 5.263 (range 
5.03-5.43, p = 0.005-0.0001).  
Patients should be informed about the 
risks of non-infectious related complications 
as part of the consent process. Transfusion 
Related Acute Lung Injury (TRALI) and 
hemolytic transfusion reactions are major 
contributors to transfusion related 
complications.
11
 TRALI is a process that 
mirrors Acute Respiratory Distress 
Syndrome, occurring after allogeneic blood 
transfusion. TRALI has gained recognition 
as a clinical phenomenon, however, it may 
be under-recognized and under-reported.
12
 
Hemolytic transfusion reactions can be due 
to incompatible ABO match or from minor 
antibodies not tested routinely. Hemolytic 
reactions may result in febrile illness, shock, 
and death.  
The US Food and Drug Administration 
requires reporting of suspected transfusion 
reactions if there is an associated fatality.
10
  
The additional impact on patient outcomes 
must be considered with blood transfusion. 
Furthermore, the costs associated with 
adverse outcomes from blood transfusion 
add to the expenditure for each unit given. 
Comment. Based on evidence from the 
TRICC trial,
6
 blood transfusion will not 
improve Ms. Garcia’s mortality risk at this 
time. 
 
Use of Blood is Under Increasing Scrutiny 
You are an involved member of the 
medical staff at your local hospital. The 
Chief of Staff approaches you one day 
and states that she is concerned about the 
high use of blood products in your 
institution and wants to know more 
about the regulatory developments in 
this area. She asks you to investigate and 
report back to the Quality Committee for 
the hospital. What are the latest regul-
atory developments? What guidelines 
are medical societies developing 
regarding blood transfusion? 
 
In 2007, The Joint Commission (TJC) 
convened a stakeholders meeting to examine 
the evidence regarding patient blood 
management. A Technical Advisory Panel 
was convened in 2008 and drafted measures 
for testing. The measures were pilot tested in 
multiple hospitals across the country. The 
Technical Advisory Panel recommended the 
final measures with modification and these 
were submitted to the National Quality 
Forum (NQF) in November 2010.
13
 
Although the Patient Blood Management 
Performance Measures Project has not been 
endorsed for national use, it serves as a tool 
for healthcare organizations to evaluate 
blood utilization and the transfusion process.  
As TJC examines and codifies practices 
in transfusion medicine, so are other medical 
organizations. The Society of Thoracic 
Surgeons (STS) and Society of 
Cardiovascular Anesthesiologists jointly 
have developed recommendations regarding 
blood transfusion, blood conservation, and 
anemia management.
14
 In its outcomes 
research, STS measures blood use by 
participating hospitals and physicians. These 
data are provided to participating physicians 
with comparative analysis to their counter-
parts at other institutions. The AABB 
(formerly the American Association of 
Blood Banks) has published practice 
guidelines on red cell transfusion to guide 
clinicians further in the appropriate 
indications for transfusion.
15
 The Eastern 
Association for Surgery of Trauma (EAST) 
and the American College of Critical Care 
Medicine (ACCM) have divided guidelines 
into seven categories for appropriate blood
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Table 1. The Joint Commission Patient Blood Management (PBM) Performance Measures 
Project.
11 
PBM-01: Transfusion Consent 
 
Patients of all ages with a signed consent who received 
information about the risks, benefits, and alternatives of 
transfusion prior to the initial transfusion of red blood 
cells, plasma, or platelets or the initial transfusion were 
deemed a medical emergency. 
PBM-02: RBC Transfusion 
Indication  
 
The number of transfused red blood cell (RBC) units 
with a pre-transfusion hemoglobin or hematocrit result 
and clinical indication documented from patients of all 
ages who received RBCs.  
PBM-03: Plasma Transfusion 
Indication 
 
The number of transfused plasma units (bags) with a pre-
transfusion laboratory testing result and clinical 
indication documented from patients of all ages who 
received plasma. 
PBM-04: Platelet Transfusion 
Indication 
 
The number of transfused platelet doses with pre-
transfusion platelet testing completed and clinical 
indication documented from patients of all ages who 
received platelets. 
PBM-05: Blood Administration 
Documentation 
 
The number of red blood cells, plasma, or platelet 
transfusion units/doses (bags) transfused to patients of all 
ages that had documentation of the following: patient 
identification and an order to transfuse (or Blood ID 
Number) confirmed prior to the initiation of transfusion, 
transfusion start date and time, and blood pressure, pulse, 
and temperature recorded at specific intervals. 
PBM-06: Preoperative Anemia 
Screening 
 
Select elective surgery, orthopedic, and hysterectomy 
patients 18 years and older with documentation of 
preoperative anemia screening 14-45 days before 
anesthesia start date. 
PBM-07: Preoperative Blood 
Type Testing and Antibody 
Screening 
 
Select elective orthopedic, cardiac, and hysterectomy 
surgical patients 18 years and older who had a type and 
screen or type and crossmatch ordered preoperatively and 
completed prior to anesthesia start time. 
 
Table 2.  EAST and ACCM clinical practice guideline: Red blood cell transfusion in adult 
trauma and critical care.
12 
A. Recommendations Regarding 
Indications for RBC Transfusion 
in the General Critically Ill 
Patient 
 
1. RBC transfusion is indicated for patients with 
evidence of hemorrhagic shock. (Level 1) 
2. RBC transfusion may be indicated for patients with 
evidence of acute hemorrhage and hemodynamic 
instability or inadequate oxygen delivery. (Level 1) 
3. A “restrictive” strategy of RBC transfusion (transfuse 
when Hb 7 g/dL) is as effective as a “liberal” 
transfusion strategy (transfusion when Hb 10 g/dL) in 
critically ill patients with hemodynamically stable 
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anemia, except possibly in patients with acute 
myocardial ischemia. (Level 1) 
4. The use of only Hb level as a “trigger” for transfusion 
should be avoided. Decision for RBC transfusion 
should be based on an individual patient’s 
intravascular volume status, evidence of shock, 
duration and extent of anemia, and cardiopulmonary 
physiologic parameters. (Level 2) 
5. In the absence of acute hemorrhage RBC, transfusion 
should be given as single units. (Level 2) 
6. Consider transfusion if Hb 7 g/dL in critically ill 
patients requiring mechanical ventilation (MV). There 
is no benefit of a “liberal” transfusion strategy 
(transfusion when Hb 10 g/dL) in critically ill patients 
requiring MV. (Level 2) 
7. Consider transfusion if Hb 7 g/dL in resuscitated 
critically ill trauma patients. There is no benefit of a 
“liberal” transfusion strategy (transfusion when Hb 10 
g/dL) in resuscitated critically ill trauma patients. 
(Level 2) 
8. Consider transfusion if Hb 7 g/dL in critically ill 
patients with stable cardiac disease. There is no 
benefit of a “liberal” transfusion strategy (transfusion 
when Hb 10 g/dL) in critically ill patients with stable 
cardiac disease. (Level 2) 
9. RBC transfusion should not be considered as an 
absolute method to improve tissue oxygen 
consumption in critically ill patients. (Level 2) 
10. RBC transfusion may be beneficial in patients with 
acute coronary syndromes (ACS) who are anemic (Hb 
8 g/dL) on hospital admission. (Level 3) 
B. Recommendations Regarding 
RBC Transfusion in Sepsis 
 
1. There are insufficient data to support Level 
recommendations on this topic. 
2. The transfusion needs for each septic patient must be 
assessed individually since optimal transfusion 
triggers in sepsis patients are not known and there is 
no clear evidence that blood transfusion increases 
tissue oxygenation. (Level 2) 
C. Recommendations Regarding 
RBC Transfusion in Patients at 
Risk for or With Acute Lung 
Injury (ALI) and ARDS (Acute 
Respiratory Distress Syndrome) 
are common clinical sequelae of 
massive transfusion. Prior studies 
have suggested that RBC 
1. There are insufficient data to support Level 1 
recommendations on this topic. 
2. All efforts should be initiated to avoid RBC 
transfusion in patients at risk for ALI and ARDS after 
completion of resuscitation. (Level 2) 
3. All efforts should be made to diagnose and report 
transfusion-related ALI (TRALI) to the local blood 
bank because it has emerged as a leading cause of 
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transfusion is associated with 
respiratory complications, in-
cluding ALI and ARDS that 
remains even after adjusting for 
potential confounders. 
transfusion-associated morbidity and mortality, 
despite under-diagnosis and under-reporting. (Level 
2) 
4. RBC transfusion should not be considered as a 
method to facilitate weaning from MV. (Level 2) 
D. Recommendations Regarding 
RBC Transfusion in Patients 
With Neurologic Injury and 
Diseases 
 
1. There are insufficient data to support Level 1 
recommendations on this topic. 
2. There is no benefit of a “liberal” transfusion strategy 
(transfusion when Hb 10 g/dL) in patients with 
moderate-to-severe traumatic brain injury. (Level 2) 
3. Decisions regarding blood transfusion in patients with 
subarachnoid hemorrhage (SAH) must be assessed 
individually since optimal transfusion triggers are not 
known and there is no clear evidence that blood 
transfusion is associated with improved outcome. 
(Level 3) 
E. Recommendations Regarding 
RBC Transfusion Risks 
 
1. There are insufficient data to support Level 1 
recommendations on this topic. 
2. RBC transfusion is associated with increased 
nosocomial infection (wound infection, pneumonia, 
sepsis) rates independent of other factors. (Level 2) 
3. RBC transfusion is an independent risk factor for 
multiple organ failure and systemic inflammatory 
response syndrome. (Level 2) 
4. There is no definitive evidence that prestorage 
leukocyte depletion of RBC transfusion reduces 
complication rates, but some studies have shown a 
reduction in infectious complications. (Level 2) 
5. RBC transfusions are independently associated with 
longer ICU and hospital length of stay, increased 
complications, and increased mortality. (Level 2) 
6. There is a relationship between transfusion and ALI 
and ARDS. (Level 2) 
F. Recommendations Regarding 
Alternatives to RBC Transfusion 
 
1. There are insufficient data to support Level 1 
recommendations on this topic. 
2. Recombinant human erythropoietin (rHuEpo) 
administration improves reticulocytosis and 
hematocrit and may decrease overall transfusion 
requirements. (Level 2) 
3. Hemoglobin-based oxygen carriers (HBOCs) are 
undergoing investigation for use in critically ill and 
injured patients but are not yet approved for use in the 
United States. (Level 2) 
G. Recommendations Regarding 
Strategies to Reduce RBC 
Transfusion 
1. There are insufficient data to support Level 1 
recommendations on this topic. 
2. The use of low-volume adult or pediatric blood 
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 sampling tubes is associated with a reduction in 
phlebotomy volumes and a reduction in blood 
transfusion. (Level 2) 
3. The use of blood conservation devices for reinfusion 
of waste blood with diagnostic sampling is associated 
with a reduction in phlebotomy volume. (Level 2) 
4. Intraoperative and postoperative blood salvage and 
alternative methods for decreasing transfusion may 
lead to a significant reduction in allogeneic blood 
usage. (Level 2) 
5. Reduction in diagnostic laboratory testing is 
associated with a reduction in phlebotomy volumes 
and a reduction in blood transfusion. (Level 2) 
 
transfusion in surgical and critical care 
settings.
16
 These are a few examples of the 
efforts of American medical societies to 
define when blood transfusions may be 
appropriate. 
 
Blood is Costly 
The Chief of Staff thanks you at the next 
Quality Committee meeting for your 
excellent report. During the meeting, she 
mentions that the expenditures for blood 
bank seem to be increasing each year 
and with cutbacks in funding the hospital 
needs to “reign in budgets”. What are the 
costs associated with blood transfusion? 
What impact does this have on the health 
system in the United States? 
 
Recent studies demonstrated that the 
total cost of administration of red blood cells 
is higher than the acquisition costs. Shander 
et al. showed that acquisition cost alone of 
RBCs ranged from $150-$248 per unit.
17
 
After accounting for direct and indirect costs 
of administration, total costs per unit of 
blood ranged from $522-$1183. Costs for 
the two US hospitals were $726-$1183 per 
unit of blood given. Using these results and 
Department of Health and Human Services 
statistics for blood transfusion, the estimated 
acquisition costs for hospitals per year is 
more than $3 billion.
14
 Total transfusion 
costs are between $10.2 and $15.4 billion. 
These studies do not take into account other 
potential costs such as lost productivity of 
healthcare workers (as they provide 
additional care to patients receiving a blood 
transfusion) and management of adverse 
transfusion outcomes. 
 
Perioperative Anemia is Best Treated 
Proactively, Not Reactively 
Raj Sharma is a 69-year-old man from 
your community who is to undergo 
coronary artery bypass surgery in four 
weeks. On pre-operative screening, he 
has a hemoglobin of 8.5 g/dL. He has 
iron deficiency anemia. He is referred to 
a gastroenterologist for evaluation and 
colonoscopy. What interventions would 
be indicated to treat his anemia? Will 
treating his anemia change his risk for 
transfusion peri-operatively? 
 
The prevalence of anemia in the pre-
operative surgical patient may be up to 76%, 
depending on the type of surgery and other 
medical comorbidities.
18
 This patient 
population may benefit significantly from 
intervention to correct anemia before further 
blood loss is incurred. A British medical 
society has adopted guidelines that 
evaluation and treatment of anemia before 
surgery should be requisite.
19
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In non-cardiac surgery, pre-operative 
anemia is an independent predictor of post-
operative mortality.
20,21
 The lower the pre-
operative hemoglobin is, the higher the 
mortality risk. In orthopedic surgery, pre-
operative anemia confers increased risk for 
peri-operative blood transfusion.
22,23
 
Treatment with preoperative intravenous 
iron is effective in increasing hemoglobin in 
orthopedic patients.
24,25
 Patients who 
received pre-operative epoetin alfa then 
underwent large joint arthroplasty (hip or 
knee) showed improvement in perioperative 
hemoglobin and decreased risk for blood 
transfusion.
26-28
 Erythropoietin use de-
creased exposure to perioperative allogeneic 
transfusion in orthopedic and cardiac 
surgery.
29
 Oral iron supplementation for at 
least two weeks prior to colorectal cancer 
surgery increases hemoglobin values in 
anemic patients and reduces the need for 
intraoperative transfusion.
30 
Pre-operative anemia is a significant risk 
factor for worsened outcomes in the peri-
operative setting. There may be several 
reasons that it is not treated more 
aggressively: (1) Medical providers have 
become “immune” to the presence of anemia 
in patients. Anemia is seen so commonly 
that many providers may ignore a low 
hemoglobin of 8 g/dL and explain that “it 
could be worse”. However, the converse 
argument should be made that “it could be 
better”. (2) Providers may not want to take 
time to address the problem proactively and 
instead take the reactive approach of giving 
a blood transfusion if the hemoglobin 
declines sharply after surgery. (3) Many 
providers may be unaware of alternative 
approaches that exist and the evidence for 
using them. 
Comment. In the case of Mr. Sharma, 
administration of parenteral iron 4-6 weeks 
prior to surgery to correct his iron deficiency 
is indicated. Oral iron may be insufficient to 
correct his iron deficiency and consequent 
anemia in time for surgery. Intravenous iron 
is much safer in its current preparations than 
compared to previous preparations. It can be 
given on an outpatient basis in an infusion 
center. Intravenous iron, when prescribed 
for the indication of iron deficiency anemia, 
often does not require insurance pre-
authorization. 
 
Patient Blood Management (PBM): 
Applying it to your Practice 
Janet Smith is a 55-year-old woman who 
is a nurse in your practice. She needs to 
have a total hip arthroplasty for a long-
standing arthritis and related debility. 
She is well-read and knows that there are 
risks with blood transfusion and she 
would like to avoid this if at all possible. 
She does not want to risk being exposed 
to hepatitis C like Mr. Jones. What 
interventions can be offered to her to 
reduce her risk for peri-operative 
transfusion? 
 
Blood transfusion has significant risks 
associated with its use. Clearly, there are 
appropriate circumstances where it is 
indicated. However, medical providers need 
to be more judicious in deciding when to 
transfuse. In a 2011 systematic review, 
Wilkinson found that gaps in the medical 
evidence and poor methodology of trials, 
particularly in the past, did not provide a 
strong evidence base for the use of red blood 
cell transfusions.
31
 
PBM is the application of evidence-
based concepts designed to maintain 
hemoglobin concentration, minimize blood 
loss, and optimize hematopoiesis. 
Pragmatically this means: (1) treating 
anemia proactively, (2) delaying surgical or 
invasive interventions until anemia can be 
corrected, (3) utilizing mechanical and 
medical interventions to minimize bleeding 
and blood loss at the time of surgery, (4) 
using blood products with an evidence-
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based approach, (5) optimizing physiologic 
tolerance of anemia.
32
 This requires a shift 
in mindset of the provider from the old 
approach of “give blood when the patient 
needs it” to the new approach of “optimize 
the patient and then only give blood once 
other measures have been taken”. 
PBM programs are being formalized in 
many hospitals across the country. The 
individual components have been shown to 
be effective in multiple clinical settings. A 
comprehensive PBM program in cardiac 
surgery was effective at reducing blood 
transfusion rates compared to hospitals 
without such a program.
33
 Furthermore, 
safety was demonstrated in the PBM 
approach with comparatively fewer deaths 
and reduced complications. 
Comment. Screening for anemia prior to 
surgery is indicated. Timely treatment of 
anemia is key to reducing Ms. Smith’s risk 
for transfusion. Some patients may ask 
about pre-operative autologous donation 
(PAD), which has been shown to have 
mixed outcomes. Discussion of PAD is not 
within the scope of this article and should 
only be considered in the peri-operative 
setting if other blood management strategies 
have failed. 
 
Conclusions 
While the safety of blood products has 
improved in regards to quality of the 
product, there are significant clinical 
concerns regarding transfusion of allogeneic 
blood. Providers need to understand the 
risks and benefits of transfusion and counsel 
patients accordingly. When possible, a 
proactive approach to evaluating and 
treating anemia should be taken. Patient 
Blood Management is a comprehensive 
approach to treating anemia and reducing 
unnecessary blood transfusions. 
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